A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir

Oral direct-acting antivirals (DAAs) are the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the first agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. More recently, ombitasvir/paritaprevir/ritonavir is also recommend...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarao, Kazuo, Yamada, Kouzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498963/
https://www.ncbi.nlm.nih.gov/pubmed/28690490
http://dx.doi.org/10.1159/000462965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498963/
https://www.ncbi.nlm.nih.gov/pubmed/28690490
http://dx.doi.org/10.1159/000462965

Ejemplares similares